PubMed Health⌕ Search

Biomedical subjects

E L Nasonov

Publications and source records attributed to E L Nasonov.

At least 19 recordsLinked to original sources
PubMed2003

[Bone mineral density in idiopathic inflammatory myopathies].

The study was undertaken to examine the impact of glucocorticoid therapy (GCT) on mineral bone density (MBD) in patients with idiopathic inflammatory myopathies. Double-energy X-ray absorptiometry was used to determine MBD of the vertebral column and proximal femur in 42 females (30 with the preserved menstrual cycle (PMC), 12 in postmenopause (PMP) with polymyositis/dermatomyositis (PM/DM). All the patients received GCT. A random population sample including 106 females aged 20 to 69 years formed a control group. MBD of the neck of the femur was significantly lower in patients from all age groups, in the lumbar vertebral column in young (20-29 years) and old (over 50 years) females than in the controls. The development of osteoporosis (OP) was more frequently observed in PMP females: OP in the lumbar spine was in 16.7 and 66.7% of the PMC and PMP females, respectively; that in the neck of the femur was in 11 and 33%. There was no relationship between MBD and the specific features of GCT, namely the duration, cumulative dose, and the maximum dose. There was a reduction in MBD in patients with PM/DM on GCT in all age groups, more frequently in PMP patients.

Absorptiometry, Photon↗
PubMed2003

[Soluble receptors of TNF-alpha with molecular mass 55 kDa in rheumatoid arthritis: clinical role].

UNLABELLED: To evaluate clinical implications of the serum level of soluable receptors of tumor necrosis factor alpha (TNFa) with molecular mass 55 kDa (rTNF-55R) in rheumatoid arthritis, serum levels of rTNF-55R and rTNF-75R were measured with the use of radioimmunoassay in 76 RA patients, 38 donors and in 25 RA patients, 10 donors, respectively. RESULTS: Elevated serum level of rTNF-55R was recorded in 55.3% RA patients. This level correlated with basic clinical and laboratory parameters of RA, the disease activity, values of DAS indices. It is concluded that a serum level of rTNF-55R adequately reflects clinico-laboratory activity of RA and its measurement can be used for assessment of RA activity and treatment efficiency.

Adolescent↗
PubMed2003

[Use of monoclonal antibodies to tumor necrosis factor (remicade) in rheumatoid arthritis: preliminary results].

AIM: To study effectiveness and tolerance of monoclonal antibodies to tumor necrosis factor (the drug remicade) in patients with rheumatoid arthritis (RA). MATERIAL AND METHODS: Remicade treatment results are considered for 25 RA patients receiving methotrexate the activity of which was inadequate for these patients. Remicade was infused intravenously in a dose 200 mg 4 times for 22 weeks. RESULTS: Remicade produced positive clinical and laboratory effects as early as the first infusion. The response was observed during 22 weeks of the treatment in 17 of 25 patients. Remicade tolerance was good. One patient failed the treatment because of development of collapse. CONCLUSION: Pilot results of remicade trial point to its high therapeutic potential and perspectives in rheumatology.

Adult↗
PubMed2003

[Effects of pulse-therapy on natural anticoagulant system of the endothelium in nonspecific aortoarteritis].

AIM: To investigate the influence of pulse-therapy on anticoagulant system of the endothelium in patients with nonspecific aortoarteritis. MATERIAL AND METHODS: Eleven patients (9 females and 2 males, mean age 33.4 +/- 8.8 years, the disease duration 5.8 +/- 5.7 years) with nonspecific aortoarteritis were examined. 9 patients had the third anatomic type of the disease with affection of the aortic arch and abdominal aorta vessels, 2 patients had the first anatomic type with isolated affection of the aortic arch. The patients received a standard three day course of pulse-therapy (PT) with glucocorticosteroids (GCS) (metipred in a dose 1000 mg/day or dexametasone in a dose 2 mg/kg/day) with a single dose of cytostatic (CS) (cyclophosphamide in a dose 10 mg/kg b.w.) during the first infusion. Further PT consisted of monthly single infusion of GCS and CS in the above doses for 9 to 12 months. Examination of the patients was carried out before the treatment and on the treatment day 4 and 20 and follow-up month 3, 6 and 12. Estimation of clinical activity was carried out according to BVAS. Levels of protein C, S, antithrombin III were measured by ELISA in plasma. Activities of protein C, antithrombin III and plasminogen were determined by the optical assay with chromogenic substrates. RESULTS: Before the start of the treatment BVAS was 6.8 +/- 4.3. During the follow-up mean scores of BVAS were significantly lower than before the pulse-therapy (2.7 +/- 2.2; 2.5 +/- 3.9; 3.1 +/- 5.1; 1.8 +/- 2.6 and 1.7 +/- 1.7, respectively; p < 0.05). Prior to the treatment, a mean level of protein C was 86.6 +/- 37.5% and range of its activity 175.2 +/- 112.9%. On the fourth day after pulse-therapy a mean concentration of protein C increased (128.8 +/- 29.0%; p < 0.05) while activity of protein C tended to a decrease on the 20th day (99.2 +/- 17.6; p > 0.05). There were no significant differences in the levels of protein S, antithrombin III and its activity, activity of plasminogen in the course of PT. CONCLUSION: PT has a good anti-inflammatory effect in the absence of unfavorable influence on anticoagulant system of the endothelium in patients with nonspecific aortoarteritis.

Adult↗
PubMed2003

[Issues related to atherosclerotic thrombosis in rheumatology].

Published data and independent author's information related with the mechanisms of development of atherosclerotic vascular lesions in inflammatory rheumatic diseases are under discussion in the article. A conclusion is made on a tense relationship between the atherosclerotic vascular lesions and thrombotic complications in systemic lupus erythematosus (SLE) and in rheumatoid arthritis (RA), on the one hand, and an impaired immunity system, which is a trigger for such diseases, on the other hand. A further study of this issue can be not only of an important theoretical but also of a big practical significance, which is related with designing new approaches towards prevention and treatment of atherosclerotic vascular lesions.

Adult↗
PubMed2002

[Acute phase proteins and recurrence of angina after effective coronary angioplasty].

AIM: Analysis of relationships between clinical characteristics of the patients, high concentration of acute phase proteins--fibrinogen, C-reactive protein (CRP), activity of the inhibitor of type 1 plasminogen activator (PAI-1)--and frequency of angina recurrence after successful coronary angioplasty (CA). MATERIAL AND METHODS: The trial included 53 patients after successful CA for a single hemodynamically significant stenosis. Peripheral blood was examined for plasm fibrinogen, CRP, activity of PAI-1 one day before and 2 days, 3 and 6 months after CA. After 12-month follow-up the patients were divided into two groups: angina-free patients (n = 37) and with recurrent angina (n = 16). RESULTS: Significant differences between the above groups were in PAI-1 activity 3 and 6 months after CA, in CRP initially, on day 2, after 6 months after CA (p < 0.05) but multifactor analysis has found that only CRP level both initial and on day 2 after CA is an independent predictor of recurrent angina pectoris after successful CA. CONCLUSION: An anginal recurrence after successful CA can be predicted by the initial and postoperative day 2 levels of CRP.

Acute-Phase Proteins↗
PubMed2002

[Soluble adhesion molecules in antiphospholipid syndrome associated with systemic lupus erythematosus and in primary antiphospholipid syndrome].

AIM: To evaluate clinical implications of measurements of the level of soluble cell molecules of adhesion (sCMA) in systemic lupus erythematosus (SLE) with antiphospholipid syndrome (APS) and primary APS (PAPS). MATERIAL AND METHODS: Serum levels of sP-selectine, sE-selectine, sVCAM-1 were determined with enzyme immunoassay (R&D, USA) in 23 SLE with APS, 15 SLE patients free of APS and 19 patients with PAPS. RESULTS: Mean levels of sE-selectine and sVCAM-1 in SLE patients with APS, PAPS and SLE was higher than in donors. Elevated mean levels of sP-selectine were observed only in SLE patients free of APS. These patients also showed a correlation between sVCAM-1 level and the disease activity (p < 0.01). CONCLUSION: The development of immunopathological process in APS is associated with increased concentration of sCMA.

Adult↗
PubMed2002

[Clinical and pathogenic significance of tumor necrosis factor-alpha in systemic lupus erythematosus].

AIM: To examine the level of tumor necrosis factor-alpha (TNFa) in the sera from patients with systemic lupus erythematosus (SLE) and its clinical and pathogenic role. MATERIAL AND METHODS: TNFa was measured with ELISA (Immunogenetics N.V., Belgium) in the sera from 147 SLE patients (70 men and 77 women). The results were compared with those of 20 healthy subjects. RESULTS: TNFa elevated concentrations were found in 49% examinees with SLE. Concentration of TNFa, SLE activity and development of antiphospholipid syndrome correlated. CONCLUSION: The findings indicate that TNFa is involved in pathogenesis of SLE. Quantitation of TNFa may serve a useful tool for monitoring SLE activity.

Adult↗
PubMed2002

[Current approaches to assessment of rheumatoid arthritis activity].

AIM: To compare domestic criteria of RA activity and the disease activity scores (DAS). MATERIAL AND METHODS: Russian criteria of RA activity and DAS were used in 99 RA patients. RESULTS: It is shown that RA activity by DAS is higher than when it is assessed by criteria practiced in Russia. CONCLUSION: Further studies are necessary to examine clinical value of DAS criteria.

Arthritis, Rheumatoid↗
PubMed2002

[Corticosteroids in the treatment of secondary antiphospholipid syndrome].

The study of changes in the levels of antiphospholipid antibodies (aPL) and clinical manifestations of antiphospholipid syndrome (APS) in response to corticosteroids in secondary APS in patients with systemic lupus erythematosus (SLE) included 219 patients (28 males and 191 females) with APS observed at least for 3 years. aPL in the blood were measured each half of year. Mean age of the patients was 31.2 +/- 11.1 years, mean duration 8.6 +/- 5.2 years. The patients were divided into 3 groups: 54 patients (persistently positive) of group 1 had IgG-anticardiolipin antibodies (aCL) in the blood for the whole period of the observation, were positive by lupus anticoagulant (LA). 73 patients of group 2 were initially aPL-positive, but aPL levels fluctuated in the observation period from positive to negative and vice versa. 92 patients of group 3 had no aPL. For 3-year follow-up 25% of SLE patients were aPL positive, 42%--negative, aCL levels fluctuated in 33%. No APS symptoms were observed in 9%, 33% of groups 1 and 2, respectively, but APS symptoms appeared in the observation period. 10% of group 3 had some aPL-associated signs. aCL levels did not depend on mean daily dose of corticosteroids in groups 1 and 2 initially and within the follow-up. Frequency of LA, irrespective of corticosteroids dose, was significantly higher initially vs that in the follow-up. In spite of correlation between aPL positivity and SLE activity, depressed activity of the disease during the treatment did not entail a significant lowering of a PL levels in the follow-up. Thus, corticosteroids in APS in SLE patients influence LA more than aCL. SLE activity, corticosteroids therapy in APS are independent factors affecting aPL. Detection of aCL and LA in SLE is not the cause of prescription of high-dose corticosteroids.

Adult↗
PubMed2002

[Soluble vascular adhesion-1 molecule in Sneddon syndrome: clinical and prognostic value].

Clinical significance of a soluble vascular adhesion-1 molecule (pVCAM-1) in Sneddon's syndrome (SS) was studied in 48 SS patients by examination of serum pVCAM-1 level using enzyme immunoassay (R&D, USA). High serum concentration of pVCAM-1 registered in 62.6% of SS patients was associated with extracerebral thromboses, not with severity of cerebral vessel damage. Lethal outcomes for 2 years of follow-up occurred more frequently in patients with a high basal level of pVCAM-1 than in patients with normal level. Thus, development of the pathological process in SS is associated with elevated concentration of serum pVCAM-1 and may serve an additional laboratory indicator of developing extrabrain thrombotic disorders and marker of unfavourable prognosis.

Female↗
PubMed2002

[Cardiological aspects of the antiphospholipid syndrome. Part I. Valvular lesions in the primary and secondary antiphospholipid syndrome and systemic lupus erythematosus].

AIM: To assess prevalence of cardiac valvular lesions in patients with primary (P) antiphospholipid syndrome (APLS) and systemic lupus erythematosus (SLE) with and without secondary APLS. MATERIAL AND METHODS: Patients with PAPLS (n=56, 15 men and 41 women), SLE and APLS (n=88, 23 men, 65 women) and SLE without APLS (n=51, 19 men, 32 women) were followed up for 9 years. Serological markers of APLS were anticardiolipin antibodies and lupus anticoagulant. RESULTS: Prevalence of various heart defects was the highest in PAPLS (43%) compared with SLE with APLS (c2=5.6, p=0.001) and SLE without APLS (c2=9.3, p=0.0002). In secondary APLS prevalence of valvular involvement was 27% what was substantially more than in SLE without APLS (4%) (c2=7.2, p=0.0007). Changes of mitral valve cusps and mitral regurgitation were found in 33, 41 and 50% of patients with SLE, SLE with APLS and PAPLS, respectively. Pronounced mitral regurgitation and valve defects were significantly more frequent in patients with any APLS compared with those with SLE without APLS. Thickening of aortic cusps was significantly more frequent in patients with PAPLS compared with patients with SLE (with and without APLS). Changes of tricuspid valve were significantly more frequent in patients with any APLS. Progression of valvular pathology was observed in 2 patients with SLE and APLS after 4 and 5 years of follow up. During 9 years thrombotic complications developed in 8 patients with APLS and valvular lesions (6 strokes, 2 retinal thromboses). CONCLUSION: An association exists between presence of APLS and various cardiac valvular lesions. Lesions of aortic valve are associated with PAPLS: Development of valvular pathology in patients with SLE and PAPLS during follow up dictates the necessity to monitor echocardiographical parameters and titers of anticardiolipin antibodies.

Adolescent↗